Review of safety assessment methods used in pediatric psychopharmacology

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 42, Issue 6, 2003, Pages 627-633

  Greenhill, Laurence L ^a   Vitiello, Benedetto ^b   Riddle, Mark A ^c   Fisher, Prudence ^a   Shockey, Erin ^a   March, John S ^d   Levine, Jerome ^e   Fried, Jane ^a   Abikoff, Howard ^f   Zito, Julie M ^g   McCracken, James T ^h   Findling, Robert L ⁱ   Robinson, James ^e   Cooper, Thomas B ^e   Davies, Mark ^a   Varipatis, Elena ^c   Labellarte, Michael J ^c   Scahill, Lawrence ^j   Walkup, John T ^c   Capasso, Lisa ^a   Rosengarten, Jennifer ^a   more..

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Nathan Kline Institute   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Adverse events; Children; Drug safety; Psychopharmacology; Treatment

Indexed keywords

PSYCHOTROPIC AGENT;

DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; ADOLESCENT; CHILD; CLINICAL TRIAL; DRUG THERAPY; FEMALE; HEALTH CARE QUALITY; MALE; PEDIATRICS; PRESCHOOL CHILD; SAFETY;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DRUG THERAPY; FEMALE; HUMANS; MALE; PEDIATRICS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; QUALITY ASSURANCE, HEALTH CARE; SAFETY;

EID: 0642311903     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CHI.0000046841.56865.37     Document Type: Article

References (71)

1. Barkley RA, McMurray MB, Edelbrock CS, Robbins K (1990), Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86:184-192
2. Biederman J, Lopez FA, Boeliner SW, Chandler MC (2002), A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics 87:221-225
3. Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995), Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 56:87-93
4. Castle WM (1999), Problems in assessing drug safety: a plea for improved methodology and a possible route. Drug Inf J 123:875-878
5. Conners CK, Arnold LE, Lindsay RL et al. (2002), A double-blind, randomized, placebo-controlled withdrawal trial of d-threo-methylphenidate hydrochloride (Focalin™) in children with attention-deficit/hyperactivity disorder. Pediatrics 88:44-59
6. Cooper MA, Groll A (2001), A case of chronic pancreatic insufficiency due to valproic acid in a child. Can J Gastroenterol 15:127-130
7. DeVeaugh-Geiss J, Moroz G, Biederman J et al. (1992), Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. J Am Acad Child Adolesc Psychiatry 31:45-49
8. DuPaul G (1996), Methylphenidate effects on children with attention deficit hyperactivity disorder: self-report of symptoms, side effects and self esteem. J Attention Disord 1:3-15
9. Gillberg C, Melander H, von Knorring A et al. (1997), Long-term central stimulant treatment of children with attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Arch Gen Psychiatry 54:857-864
10. Greenhill L, Swanson J, Vitiello B et al. (2001), Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA Titration Trial. J Am Acad Child Adolesc Psychiatry 40:180-188
11. Greenhill LL, Findling RL, Swanson JM (2002), A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109:e39-e44
12. Hollister LE, Jones JK, Fisher S (1994), Post-marketing surveillance of drugs. In: Clinical Evaluation of Psychotropic Drugs Principles and Guidelines, Prien RF, Robinson DS, eds. New York: Raven, pp 217-235
13. Ioannidis JPA, Lau J (2001), Safety reporting in clinical trials. JAMA 285.2076-2078
14. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R (1999), Treatment of Attention-Deficit/Hyperactivity Disorder Evidence Report/Technology Assessment No. 11 (prepared by McMaster University under contract 290-0017) (No. 00-E005). Rockville, MD: Agency for Healthcare Research and Quality
15. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB (1999), Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557-565
16. Keller MB, Ryan ND, Strober M et al. (2001), Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772
17. Laughren T, Levine JD, Levine JG, Thompson WL (1994), Premarketing safety evaluation of new drugs. In: Clinical Evaluation of Psychotropic Drug: Principles and Guidelines, Prien RF, Robinson DS, eds. New York: Raven, pp 185-215
18. Levine J, Schooler NR (1986), SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22:343-381
19. March JS, Biederman J, Wokow R et al. (1998), Sertraline in children and adolescents with obsessive-compulsive disorder. JAMA 280:1752-1756
20. Medical Letter (1990), Sudden death in children treated with a tricyclic antidepressant. Med Lett 32:53
21. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee R, Spencer T, Atomoxetine ADHD Study Group (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83-e91
22. MTA Cooperative Group (1999), 14-Month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 56:3073-1086
23. Otsubo S, Huruzono T, Kobae H, Yoshimi S, Miyata K (1995), Pancreatitis with normal serum amylase associated with sodium valproate: a case report. Brain Dev 17:219-221
24. Rabkin JG, Markowitz JS (1986), Side effect assessment with SAFTEE: pilot study of the instrument. Psychopharmacol Bull 22:389-396
25. Research Unit on Pediatric Psychopharmacology Anxiety Study Group (2001), Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
26. Research Unit on Pediatric Psychopharmacology Autism Network (2002), Risperidone in children with autism and serious behavior problems. N Engl J Med 347:314-321
27. Riddle MA, Reeve EA, Yaryura-Tobias JA et al. (2001), Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222-229
28. Safer DJ, Zito JM, Gardner JE (2001), Pemoline hepatotoxicity and post-marketing surveillance. J Am Acad Child Adolesc Psychiatry 40:622-629
29. Scheffner D, Konig S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S (1988), Fatal liver failure in 16 children with valproate therapy. Epilepsia 29:530-542
30. Swanson J, Flockhart D, Udrea D, Cantwell D, Conner D, Williams L (1995), Clonidine in the treatment of ADHD: questions about the safety and efficacy. J Child Adolesc Psychopharmacol 5:301-305
31. Swanson J, Gupta S, Lam A et al. (2003), Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 60:204-211
32. Tourette's Syndrome Study Group (2002), Treatment of ADHD in children with tics. Neurology 58:527-536
33. Vitiello B, Jensen P (1995), Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 31:75-81
34. Vitiello B, Jensen P (1997), Medication development and testing in children and adolescents. Arch Gen Psychiatry 54:871-876
35. Vitiello B, Riddle MA, Greenhill LL et al. (2003), How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 42:634-641
36. Wolraich M, Greenhill LL, Abikoff H et al. (2001), Randomized controlled trial of OROS methylphenidate QD in children with attention-deficit hyperactivity disorder. Pediatrics 108:883-892
37. Zito JM, Safer DJ, dosReis S, Gardiner J, Boles N, Lynch F (2000), Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030
38. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999), Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:e20
39. Brewer T, Colditz GA (1999), Postmarketing surveillance and adverse drug reactions: current perspectives and future needs, JAMA 281:824-829
40. Brown EG, Wood L, Wood S (1999), The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 20:109-117
41. Carlson GA, Loney J, Salisbury H, Kramer JR, Arthur C (2000), Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J Child Adolesc Pychopharmacol 10:175-184
42. Culy CR, Goa KL (2000), Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drug 2:299-330
43. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline BA, Menander KB (1987), Valproic acid hepatic fatalities: a retrospective review. Neurology 37:379-385
44. Edwards JG, Inman WHW, Pearce GL, Rawson NS (1991), Prescription-event monitoring of 10,895 patients treated with alprazolam. Br J Psychiatry 158:387-392
45. Farwell JR, Lee YJ, Jirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB (1990), Phenobarbital for febrile seizures: effects on intelligence and on seizure recurrence. N Engl J Med 322:364-369
46. Food and Drug Administration (1995), COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. Springfield, VA: US Department of Commerce (available from the National Technical Information Service, 5285 Port Royal Road, Springfield, VA 22161; 703-487-4650)
47. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA (1989), Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 96(2 pt 2 suppl):647-655
48. Greenhill LL, Vitiello B, Riddle MA et al. (2003), Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:627-633
49. Herbst AL, Ulfelder H, Poskanzer DC (1971), Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284:878-881
50. Hollister LE, Jones JK, Fisher S (1994), Post-marketing surveillance of drugs. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS, eds. New York: Raven, pp 217-235
51. Inman WHW (1981), Postmarketing surveillance of adverse drug reactions in general practice. Br Med J 262:1216-1217
52. Ioannidis JPA, Lau J (2001), Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 285:437-443
53. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB (1999), Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38:557-565
54. Klein RG, Landa B, Mattes JA, Klein DF (1988), Methylphenidate and growth in hyperactive children: a controlled withdrawal study. Arch Gen Psychiatry 45:1127-1130
55. Laska EM, Klein DK, Lavori PW, Levine J, Robinson DS (1994), Design issues for the clinical evaluation of psychotropic drugs. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS, eds. New York: Raven, pp 29-67
56. Laughren T, Levine JD, Levine JG, Thompson WL (1994), Premarketing safety evaluation of new drugs. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, Prien RF, Robinson DS, eds. New York: Raven, pp 185-215
57. Lavori PW (1986), Side effects data analysis. Psychopharmacol Bull 22:402-404
58. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH (2000), A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 23:533-542
59. McMaster University Evidence-Based Practice Center (1998), The Treatment of Attention-Deficit/Hyperactivity Disorder: An Evidence Report (Contract 290-97-0017). Washington, DC: Agency for Health Care Policy and Research (available at www.ahrq.gov/clinic/epcsums/adhdsum.htm)
60. Moll GH, Hause S, Ruether E, Rothenberger A, Huether G (2001), Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 11:15-24
61. Riddle MA, Kastelic EA, Frosch E (2001), Pediatric psychopharmacology. J Child Psychol Psychiatry 42:73-90
62. Riddle MA, Nelson JC, Kleinman CS et al. (1991), Sudden death in children receiving Norpramin: a review of three reported cases and commentaries. J Am Acad Child Adolesc Psychiatry 30:104-108
63. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000), Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxerine. J Am Acad Child Adolesc Psychiatry 39:1096-1103
64. RUPP Anxiety Study Group (2001), Fluvoxamine treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285
65. Safer DJ, Zito JM, Gardner JF (2001), Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 40:622-629
66. Schachar R, Tannock R, Cunningham C, Corkum P (1997), Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 36:754-763
67. Temple R (1999), Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA 281:841-844
68. Vida S, Looper K (1999), Precision and comparability of adverse event rates of newer antidepressants. J Clin Pharmacol 19:416-426
69. Vorhees CV, Rindler JM, Minck DR (1990), Effects of exposure period and nutrition on the developmental neurotoxicity of anticonvulsants in rats: short and long-term effects. Neurotoxicology 11:273-283
70. Zito JM, Safer D, Riddle M, dosReis S (1997), Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull 33:143-147
71. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F (2000), Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030